Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm Strengthens its Board of Directors as Company Prepares for Multiple Clinical and Business Milestones in 2014
Richard Pascoe, CEO of Apricus Biosciences, and Joseph B. Saluri, Vice-President - General Counsel for Stine Seed Company, Added to KemPharm's Board Coralville, IA – Jan. 13, 2014 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer
Toggle Summary KemPharm Completes Successful End-of-Phase 2 Meeting with FDA
Clinical, Non-Clinical and CMC Development Programs on Track for Third Quarter 2014 NDA Submission North Liberty, IA – Nov. 1, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today the
Toggle Summary KemPharm Forms Physician Advisory Council Advocating "Intelligent Pain Therapeutic Development"
Pain Management Thought Leaders, Jeffrey A. Gudin, MD, and Srinivas Nalamachu, MD to Lead Council as Interest in Prodrug-Based Pain Therapeutics Builds North Liberty, IA – October 23, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new,
Toggle Summary KemPharm's KP201 Demonstrates Bioequivalence Compared to Norco® in Key Pivotal Clinical Study
Travis C. Mickle, Ph.D., President & CEO of KemPharm, to Present Results at The 7th Annual Pain Therapeutics Summit East North Liberty, IA and Boston, MA – Sept. 25, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer
Toggle Summary KemPharm Continues to Expand its Pain Therapy Pipeline with Discovery of KP606, a Novel Prodrug of Oxycodone
KP606 Introduced at PAINWeek 2013 North Liberty, IA and Las Vegas, NV – Sept. 4, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, today announced the advancement of a new pain therapy program, KP606, a
Toggle Summary KemPharm's KP201 to be Featured at PAINWeek 2013
Poster Presentation to Highlight KP201's Unique Abuse-Deterrent Properties and Its Potential to Prevent or Reduce Opioid-Induced Constipation North Liberty, IA – Aug. 28, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer
Toggle Summary KemPharm's KP201 Demonstrates Complete Metabolic Cleavage of Prodrug and Steady-State Pharmacokinetic Profiles for Hydrocodone, Hydromorphone and Acetaminophen
Clinical Study Also Indicates No Systemic Prodrug Exposure Over Multiple-Day Dosing at Maximum Daily Dose North Liberty, IA – August 26, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, today announced
Toggle Summary KemPharm, Inc. Receives Additional Notice of Allowance for Novel Prodrugs of Hydrocodone
North Liberty, IA – August 7, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for
Toggle Summary KemPharm, Inc. Appoints Gordon K. "Rusty" Johnson as Chief Operating Officer and Chief Financial Officer
30-Year Investment Banking Veteran Joins KemPharm to Strengthen its Business & Financial Operations North Liberty, IA – July 15, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today the
Toggle Summary KemPharm, Inc. Receives Patent from the USPTO for Novel Pain Drug Candidate, KP201
North Liberty, IA – June 11, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No.